English
简体中文
Total: £ 56.28
Published Date: 2025-07-10 | Pages: 100 | Tables: 99 | Medical Care
The global market for Antibody Drug Conjugate CDMO was valued at US$ 3059 million in the year 2024 and is projected to reach a revised size of US$ 7331 million by 2031, growing at a CAGR of 12.7% during the forecast period.
Antibody-Drug Conjugate (ADC) is a type of targeted cancer therapy that utilizes monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy cells. ADCs have shown promising results in treating various types of cancers.A Contract Development and Manufacturing Organization (CDMO) specializes in providing services related to the development, manufacturing, and testing of pharmaceuticals, including biologics like ADCs.
Antibody Drug Conjugates (ADCs) represent one of the fastest-growing and most sophisticated segments in targeted cancer therapy. By combining the precise targeting ability of monoclonal antibodies with the potent cell-killing effect of cytotoxic drugs, ADCs offer a powerful treatment strategy that minimizes harm to healthy tissues.
However, ADCs are among the most complex biologic-drug hybrids to manufacture — they require expertise in biologics production, high-potency active pharmaceutical ingredient (HPAPI) synthesis, advanced conjugation technology, and high-containment fill-finish capabilities.
This is where Contract Development and Manufacturing Organizations (CDMOs) come in. They provide specialized technical infrastructure and know-how for biopharma companies that want to develop and commercialize ADCs without building expensive in-house capacity.
The ADC CDMO market has grown significantly in recent years, fueled by an expanding pipeline of ADCs in clinical trials and rising numbers of commercial approvals. Leading CDMOs now offer end-to-end solutions covering monoclonal antibody production, payload synthesis, conjugation, and sterile, high-containment packaging.
Growing Number of Approved ADCs and Robust Clinical Pipeline
More than a dozen ADCs have received regulatory approval worldwide, with blockbusters like Enhertu®, Padcev®, and Polivy® demonstrating strong commercial success. At the same time, hundreds of new ADCs are in preclinical and clinical development targeting a wide range of cancers and even some non-oncology indications. This expanding pipeline fuels sustained demand for expert CDMO services from early development through to commercial scale-up.
Rising Demand for End-to-End Solutions
Pharma companies increasingly prefer one-stop CDMO partners that can handle the entire ADC value chain — from cell line development to final fill-finish — under a single quality system and contract. This integrated model simplifies supply chains, shortens development timelines, and reduces risk, giving CDMOs with full-spectrum ADC capabilities a competitive edge.
Increased Investment in High-Potency Manufacturing Capacity
As the ADC market expands, leading CDMOs are investing heavily to expand or build new high-containment suites and HPAPI production lines. This growth is critical because HPAPI synthesis and handling require specialized equipment, isolated work areas, and rigorous operator safety systems.
Companies like Lonza, WuXi XDC, Piramal Pharma Solutions, and Sterling Pharma Solutions have made significant capital investments to meet the increasing global demand.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate CDMO.
The Antibody Drug Conjugate CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody Drug Conjugate CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group
Porton Pharma Solutions
WuXi XDC
BOC Sciences
Asymchem
Catalent Biologics
3PBIOVIAN
Genscript
AGC Biologics
MabPlex
ChemExpress
Abzena
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
AbbVie Contract Manufacturing
TOT Biopharm
Huadong Medicine
Innovent Biologics
Zhenhao Biology
Porton Pharma Solutions
Segment by Type
Cleavable Linker ADCs
Non-Cleavable Linker ADCs
Segment by Application
Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cleavable Linker ADCs
1.2.3 Non-Cleavable Linker ADCs
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugate CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Small and Medium-sized Pharmaceutical Companies
1.3.3 Large Pharmaceutical Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody Drug Conjugate CDMO Market Perspective (2020-2031)
2.2 Global Antibody Drug Conjugate CDMO Growth Trends by Region
2.2.1 Global Antibody Drug Conjugate CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody Drug Conjugate CDMO Historic Market Size by Region (2020-2025)
2.2.3 Antibody Drug Conjugate CDMO Forecasted Market Size by Region (2026-2031)
2.3 Antibody Drug Conjugate CDMO Market Dynamics
2.3.1 Antibody Drug Conjugate CDMO Industry Trends
2.3.2 Antibody Drug Conjugate CDMO Market Drivers
2.3.3 Antibody Drug Conjugate CDMO Market Challenges
2.3.4 Antibody Drug Conjugate CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugate CDMO Players by Revenue
3.1.1 Global Top Antibody Drug Conjugate CDMO Players by Revenue (2020-2025)
3.1.2 Global Antibody Drug Conjugate CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Top Antibody Drug Conjugate CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody Drug Conjugate CDMO Revenue
3.4 Global Antibody Drug Conjugate CDMO Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugate CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate CDMO Revenue in 2024
3.5 Global Key Players of Antibody Drug Conjugate CDMO Head office and Area Served
3.6 Global Key Players of Antibody Drug Conjugate CDMO, Product and Application
3.7 Global Key Players of Antibody Drug Conjugate CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Drug Conjugate CDMO Breakdown Data by Type
4.1 Global Antibody Drug Conjugate CDMO Historic Market Size by Type (2020-2025)
4.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2026-2031)
5 Antibody Drug Conjugate CDMO Breakdown Data by Application
5.1 Global Antibody Drug Conjugate CDMO Historic Market Size by Application (2020-2025)
5.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibody Drug Conjugate CDMO Market Size (2020-2031)
6.2 North America Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)
6.4 North America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody Drug Conjugate CDMO Market Size (2020-2031)
7.2 Europe Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)
7.4 Europe Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugate CDMO Market Size (2020-2031)
8.2 Asia-Pacific Antibody Drug Conjugate CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Antibody Drug Conjugate CDMO Market Size (2020-2031)
9.2 Latin America Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)
9.4 Latin America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugate CDMO Market Size (2020-2031)
10.2 Middle East & Africa Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Group
11.1.1 Lonza Group Company Details
11.1.2 Lonza Group Business Overview
11.1.3 Lonza Group Antibody Drug Conjugate CDMO Introduction
11.1.4 Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.1.5 Lonza Group Recent Development
11.2 Porton Pharma Solutions
11.2.1 Porton Pharma Solutions Company Details
11.2.2 Porton Pharma Solutions Business Overview
11.2.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Introduction
11.2.4 Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.2.5 Porton Pharma Solutions Recent Development
11.3 WuXi XDC
11.3.1 WuXi XDC Company Details
11.3.2 WuXi XDC Business Overview
11.3.3 WuXi XDC Antibody Drug Conjugate CDMO Introduction
11.3.4 WuXi XDC Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.3.5 WuXi XDC Recent Development
11.4 BOC Sciences
11.4.1 BOC Sciences Company Details
11.4.2 BOC Sciences Business Overview
11.4.3 BOC Sciences Antibody Drug Conjugate CDMO Introduction
11.4.4 BOC Sciences Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.4.5 BOC Sciences Recent Development
11.5 Asymchem
11.5.1 Asymchem Company Details
11.5.2 Asymchem Business Overview
11.5.3 Asymchem Antibody Drug Conjugate CDMO Introduction
11.5.4 Asymchem Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.5.5 Asymchem Recent Development
11.6 Catalent Biologics
11.6.1 Catalent Biologics Company Details
11.6.2 Catalent Biologics Business Overview
11.6.3 Catalent Biologics Antibody Drug Conjugate CDMO Introduction
11.6.4 Catalent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.6.5 Catalent Biologics Recent Development
11.7 3PBIOVIAN
11.7.1 3PBIOVIAN Company Details
11.7.2 3PBIOVIAN Business Overview
11.7.3 3PBIOVIAN Antibody Drug Conjugate CDMO Introduction
11.7.4 3PBIOVIAN Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.7.5 3PBIOVIAN Recent Development
11.8 Genscript
11.8.1 Genscript Company Details
11.8.2 Genscript Business Overview
11.8.3 Genscript Antibody Drug Conjugate CDMO Introduction
11.8.4 Genscript Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.8.5 Genscript Recent Development
11.9 AGC Biologics
11.9.1 AGC Biologics Company Details
11.9.2 AGC Biologics Business Overview
11.9.3 AGC Biologics Antibody Drug Conjugate CDMO Introduction
11.9.4 AGC Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.9.5 AGC Biologics Recent Development
11.10 MabPlex
11.10.1 MabPlex Company Details
11.10.2 MabPlex Business Overview
11.10.3 MabPlex Antibody Drug Conjugate CDMO Introduction
11.10.4 MabPlex Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.10.5 MabPlex Recent Development
11.11 ChemExpress
11.11.1 ChemExpress Company Details
11.11.2 ChemExpress Business Overview
11.11.3 ChemExpress Antibody Drug Conjugate CDMO Introduction
11.11.4 ChemExpress Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.11.5 ChemExpress Recent Development
11.12 Abzena
11.12.1 Abzena Company Details
11.12.2 Abzena Business Overview
11.12.3 Abzena Antibody Drug Conjugate CDMO Introduction
11.12.4 Abzena Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.12.5 Abzena Recent Development
11.13 Ajinomoto Bio-Pharma Services
11.13.1 Ajinomoto Bio-Pharma Services Company Details
11.13.2 Ajinomoto Bio-Pharma Services Business Overview
11.13.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Introduction
11.13.4 Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.13.5 Ajinomoto Bio-Pharma Services Recent Development
11.14 BSP Pharmaceuticals
11.14.1 BSP Pharmaceuticals Company Details
11.14.2 BSP Pharmaceuticals Business Overview
11.14.3 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Introduction
11.14.4 BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.14.5 BSP Pharmaceuticals Recent Development
11.15 AbbVie Contract Manufacturing
11.15.1 AbbVie Contract Manufacturing Company Details
11.15.2 AbbVie Contract Manufacturing Business Overview
11.15.3 AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Introduction
11.15.4 AbbVie Contract Manufacturing Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.15.5 AbbVie Contract Manufacturing Recent Development
11.16 TOT Biopharm
11.16.1 TOT Biopharm Company Details
11.16.2 TOT Biopharm Business Overview
11.16.3 TOT Biopharm Antibody Drug Conjugate CDMO Introduction
11.16.4 TOT Biopharm Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.16.5 TOT Biopharm Recent Development
11.17 Huadong Medicine
11.17.1 Huadong Medicine Company Details
11.17.2 Huadong Medicine Business Overview
11.17.3 Huadong Medicine Antibody Drug Conjugate CDMO Introduction
11.17.4 Huadong Medicine Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.17.5 Huadong Medicine Recent Development
11.18 Innovent Biologics
11.18.1 Innovent Biologics Company Details
11.18.2 Innovent Biologics Business Overview
11.18.3 Innovent Biologics Antibody Drug Conjugate CDMO Introduction
11.18.4 Innovent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.18.5 Innovent Biologics Recent Development
11.19 Zhenhao Biology
11.19.1 Zhenhao Biology Company Details
11.19.2 Zhenhao Biology Business Overview
11.19.3 Zhenhao Biology Antibody Drug Conjugate CDMO Introduction
11.19.4 Zhenhao Biology Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.19.5 Zhenhao Biology Recent Development
11.20 Porton Pharma Solutions
11.20.1 Porton Pharma Solutions Company Details
11.20.2 Porton Pharma Solutions Business Overview
11.20.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Introduction
11.20.4 Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025)
11.20.5 Porton Pharma Solutions Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cleavable Linker ADCs
Table 3. Key Players of Non-Cleavable Linker ADCs
Table 4. Global Antibody Drug Conjugate CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Antibody Drug Conjugate CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Antibody Drug Conjugate CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Antibody Drug Conjugate CDMO Market Share by Region (2020-2025)
Table 8. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Antibody Drug Conjugate CDMO Market Share by Region (2026-2031)
Table 10. Antibody Drug Conjugate CDMO Market Trends
Table 11. Antibody Drug Conjugate CDMO Market Drivers
Table 12. Antibody Drug Conjugate CDMO Market Challenges
Table 13. Antibody Drug Conjugate CDMO Market Restraints
Table 14. Global Antibody Drug Conjugate CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Antibody Drug Conjugate CDMO Market Share by Players (2020-2025)
Table 16. Global Top Antibody Drug Conjugate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate CDMO as of 2024)
Table 17. Ranking of Global Top Antibody Drug Conjugate CDMO Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Antibody Drug Conjugate CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Antibody Drug Conjugate CDMO, Headquarters and Area Served
Table 20. Global Key Players of Antibody Drug Conjugate CDMO, Product and Application
Table 21. Global Key Players of Antibody Drug Conjugate CDMO, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody Drug Conjugate CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Antibody Drug Conjugate CDMO Revenue Market Share by Type (2020-2025)
Table 25. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Antibody Drug Conjugate CDMO Revenue Market Share by Type (2026-2031)
Table 27. Global Antibody Drug Conjugate CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Antibody Drug Conjugate CDMO Revenue Market Share by Application (2020-2025)
Table 29. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Antibody Drug Conjugate CDMO Revenue Market Share by Application (2026-2031)
Table 31. North America Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Antibody Drug Conjugate CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 46. Lonza Group Company Details
Table 47. Lonza Group Business Overview
Table 48. Lonza Group Antibody Drug Conjugate CDMO Product
Table 49. Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 50. Lonza Group Recent Development
Table 51. Porton Pharma Solutions Company Details
Table 52. Porton Pharma Solutions Business Overview
Table 53. Porton Pharma Solutions Antibody Drug Conjugate CDMO Product
Table 54. Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 55. Porton Pharma Solutions Recent Development
Table 56. WuXi XDC Company Details
Table 57. WuXi XDC Business Overview
Table 58. WuXi XDC Antibody Drug Conjugate CDMO Product
Table 59. WuXi XDC Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 60. WuXi XDC Recent Development
Table 61. BOC Sciences Company Details
Table 62. BOC Sciences Business Overview
Table 63. BOC Sciences Antibody Drug Conjugate CDMO Product
Table 64. BOC Sciences Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 65. BOC Sciences Recent Development
Table 66. Asymchem Company Details
Table 67. Asymchem Business Overview
Table 68. Asymchem Antibody Drug Conjugate CDMO Product
Table 69. Asymchem Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 70. Asymchem Recent Development
Table 71. Catalent Biologics Company Details
Table 72. Catalent Biologics Business Overview
Table 73. Catalent Biologics Antibody Drug Conjugate CDMO Product
Table 74. Catalent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 75. Catalent Biologics Recent Development
Table 76. 3PBIOVIAN Company Details
Table 77. 3PBIOVIAN Business Overview
Table 78. 3PBIOVIAN Antibody Drug Conjugate CDMO Product
Table 79. 3PBIOVIAN Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 80. 3PBIOVIAN Recent Development
Table 81. Genscript Company Details
Table 82. Genscript Business Overview
Table 83. Genscript Antibody Drug Conjugate CDMO Product
Table 84. Genscript Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 85. Genscript Recent Development
Table 86. AGC Biologics Company Details
Table 87. AGC Biologics Business Overview
Table 88. AGC Biologics Antibody Drug Conjugate CDMO Product
Table 89. AGC Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 90. AGC Biologics Recent Development
Table 91. MabPlex Company Details
Table 92. MabPlex Business Overview
Table 93. MabPlex Antibody Drug Conjugate CDMO Product
Table 94. MabPlex Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 95. MabPlex Recent Development
Table 96. ChemExpress Company Details
Table 97. ChemExpress Business Overview
Table 98. ChemExpress Antibody Drug Conjugate CDMO Product
Table 99. ChemExpress Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 100. ChemExpress Recent Development
Table 101. Abzena Company Details
Table 102. Abzena Business Overview
Table 103. Abzena Antibody Drug Conjugate CDMO Product
Table 104. Abzena Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 105. Abzena Recent Development
Table 106. Ajinomoto Bio-Pharma Services Company Details
Table 107. Ajinomoto Bio-Pharma Services Business Overview
Table 108. Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Product
Table 109. Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 110. Ajinomoto Bio-Pharma Services Recent Development
Table 111. BSP Pharmaceuticals Company Details
Table 112. BSP Pharmaceuticals Business Overview
Table 113. BSP Pharmaceuticals Antibody Drug Conjugate CDMO Product
Table 114. BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 115. BSP Pharmaceuticals Recent Development
Table 116. AbbVie Contract Manufacturing Company Details
Table 117. AbbVie Contract Manufacturing Business Overview
Table 118. AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Product
Table 119. AbbVie Contract Manufacturing Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 120. AbbVie Contract Manufacturing Recent Development
Table 121. TOT Biopharm Company Details
Table 122. TOT Biopharm Business Overview
Table 123. TOT Biopharm Antibody Drug Conjugate CDMO Product
Table 124. TOT Biopharm Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 125. TOT Biopharm Recent Development
Table 126. Huadong Medicine Company Details
Table 127. Huadong Medicine Business Overview
Table 128. Huadong Medicine Antibody Drug Conjugate CDMO Product
Table 129. Huadong Medicine Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 130. Huadong Medicine Recent Development
Table 131. Innovent Biologics Company Details
Table 132. Innovent Biologics Business Overview
Table 133. Innovent Biologics Antibody Drug Conjugate CDMO Product
Table 134. Innovent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 135. Innovent Biologics Recent Development
Table 136. Zhenhao Biology Company Details
Table 137. Zhenhao Biology Business Overview
Table 138. Zhenhao Biology Antibody Drug Conjugate CDMO Product
Table 139. Zhenhao Biology Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 140. Zhenhao Biology Recent Development
Table 141. Porton Pharma Solutions Company Details
Table 142. Porton Pharma Solutions Business Overview
Table 143. Porton Pharma Solutions Antibody Drug Conjugate CDMO Product
Table 144. Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2020-2025) & (US$ Million)
Table 145. Porton Pharma Solutions Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
Table 149. Authors List of This Report
List of Figures
Figure 1. Antibody Drug Conjugate CDMO Picture
Figure 2. Global Antibody Drug Conjugate CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antibody Drug Conjugate CDMO Market Share by Type: 2024 VS 2031
Figure 4. Cleavable Linker ADCs Features
Figure 5. Non-Cleavable Linker ADCs Features
Figure 6. Global Antibody Drug Conjugate CDMO Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Antibody Drug Conjugate CDMO Market Share by Application: 2024 VS 2031
Figure 8. Small and Medium-sized Pharmaceutical Companies Case Studies
Figure 9. Large Pharmaceutical Companies Case Studies
Figure 10. Antibody Drug Conjugate CDMO Report Years Considered
Figure 11. Global Antibody Drug Conjugate CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Antibody Drug Conjugate CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Antibody Drug Conjugate CDMO Market Share by Region: 2024 VS 2031
Figure 14. Global Antibody Drug Conjugate CDMO Market Share by Players in 2024
Figure 15. Global Antibody Drug Conjugate CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate CDMO Revenue in 2024
Figure 17. North America Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 18. North America Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)
Figure 19. United States Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. Canada Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Europe Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)
Figure 23. Germany Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. France Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. U.K. Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Italy Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Russia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Ireland Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Asia-Pacific Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Antibody Drug Conjugate CDMO Market Share by Region (2020-2031)
Figure 31. China Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Japan Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. South Korea Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Southeast Asia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. India Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Australia & New Zealand Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Latin America Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)
Figure 39. Mexico Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Brazil Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Middle East & Africa Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Antibody Drug Conjugate CDMO Market Share by Country (2020-2031)
Figure 43. Israel Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Saudi Arabia Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. UAE Antibody Drug Conjugate CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Lonza Group Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 47. Porton Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 48. WuXi XDC Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 49. BOC Sciences Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 50. Asymchem Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 51. Catalent Biologics Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 52. 3PBIOVIAN Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 53. Genscript Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 54. AGC Biologics Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 55. MabPlex Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 56. ChemExpress Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 57. Abzena Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 58. Ajinomoto Bio-Pharma Services Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 59. BSP Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 60. AbbVie Contract Manufacturing Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 61. TOT Biopharm Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 62. Huadong Medicine Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 63. Innovent Biologics Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 64. Zhenhao Biology Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 65. Porton Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
